stockportfolio.pro
Stocks / CTKB vs NPCE
CTKB vs NPCE
Cytek Biosciences, Inc. and NeuroPace, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Cytek Biosciences, Inc. (CTKB) | NeuroPace, Inc. (NPCE) | |
|---|---|---|
| Market cap | $0.5B | $0.5B |
| Revenue (latest FY) | $201.49M | $99.99M |
| Net income (latest FY) | $-66.54M | $-21.46M |
| Revenue growth (5y CAGR) | 209.5% | 19.4% |
| Net margin | -33.0% | -21.5% |
| Return on equity | -19.5% | -112.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CTKB — free Open NPCE — freeFrequently asked questions
Which is bigger, CTKB or NPCE?
NeuroPace, Inc. is larger by market capitalization — $0.5B versus $0.5B.
Which grows faster, CTKB or NPCE?
Over the last five fiscal years, Cytek Biosciences, Inc. grew revenue faster — 209.5%/yr versus 19.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.